{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:01:37Z","timestamp":1791295297929,"version":"4.1.0"},"reference-count":16,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anxiety and depression are common among psoriasis and psoriatic arthritis (PsA) patients, but rates may differ by treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To quantify the risk of incident treated anxiety, depression and mixed anxiety\u00a0+\u00a0depression in users of apremilast compared with users of other treatments for psoriasis and PsA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted two separate cohort studies of psoriasis and PsA patients treated with apremilast, tumour necrosis factor inhibitor biologics, interleukin\u201017, \u201023 or \u201012\/23 inhibitor biologics, conventional DMARDs or systemic corticosteroids in the United States MarketScan database. Cohort entry was date of first study drug after 21 March 2014. We identified cases who had a depression and\/or anxiety diagnosis with a prescription for antidepressant\/antianxiety medication within 30\u00a0days of the diagnosis code. We calculated incidence rates (IRs) and incidence rate ratios with 95% confidence intervals (CIs) for treated anxiety, treated depression and treated anxiety\u00a0+\u00a0depression per 1000 patient\u2010years (PY) among patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the psoriasis cohort, IRs for each outcome were similar between exposure categories and highest among users of systemic corticosteroids alone. IRs (95% CI) for apremilast alone were 9.2 (6.6\u201312.5), 4.6 (2.8\u20137.1) and 4.6 (2.8\u20137.1) per 1000 PY for treated anxiety, treated depression and treated anxiety\u00a0+\u00a0depression, respectively. In the PsA cohort, the rate of anxiety was highest among users of apremilast alone; rates of depression and anxiety\u00a0+\u00a0depression were similar for apremilast compared with other PsA treatments. IRs for each outcome were also high for users of corticosteroids in both the psoriasis and PsA cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with psoriasis, users of apremilast had similar rates of anxiety and depression as users of other non\u2010corticosteroid systemic psoriasis treatments. Among PsA patients, users of apremilast had similar rates of depression and anxiety\u00a0+\u00a0depression compared with users of other systemic non\u2010corticosteroid PsA drugs; however, the rate of anxiety was slightly higher.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.16231","type":"journal-article","created":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T08:35:01Z","timestamp":1579941301000},"page":"1755-1763","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database"],"prefix":"10.1111","volume":"34","author":[{"given":"C.","family":"Vasilakis\u2010Scaramozza","sequence":"first","affiliation":[{"name":"Boston Collaborative Drug Surveillance Program Lexington MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Persson","sequence":"additional","affiliation":[{"name":"Boston Collaborative Drug Surveillance Program Lexington MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.W.","family":"Hagberg","sequence":"additional","affiliation":[{"name":"Boston Collaborative Drug Surveillance Program Lexington MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2215-1067","authenticated-orcid":false,"given":"S.","family":"Jick","sequence":"additional","affiliation":[{"name":"Boston Collaborative Drug Surveillance Program Lexington MA USA"},{"name":"Boston University School of Public Health Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,28]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.508"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13891"},{"key":"e_1_2_6_4_1","first-page":"36","article-title":"Psoriasis and associated psychiatric disorders: a systematic review on etiopathogenesis and clinical correlation","volume":"9","author":"Ferreira BI","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.05.010"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17208"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.058"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.5070\/D32410041706"},{"key":"e_1_2_6_9_1","unstructured":"Celgene Corporation.Otezla (apremilast): full prescribing information. [WWW document]. URLhttps:\/\/media.celgene.com\/content\/uploads\/otezla-pi.pdf(last accessed: September 23 2019)."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.01.052"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1901-3"},{"key":"e_1_2_6_12_1","unstructured":"PickensG MoldwinE MarderWD.Healthcare spending index for employer\u2010sponsored insurance: methodology and baseline results[WWW document]2010; (November) 24. URLhttp:\/\/truvenhealth.com\/Portals\/0\/Assets\/HealthInsights\/TRU_15667_0415_HSI_ESI_WP.pdf(last accessed: September 23 2019)."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v03n0104"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.4065\/81.10.1361"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2015.04.008"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000479163"},{"key":"e_1_2_6_17_1","first-page":"46","article-title":"Systemic psoriasis therapies and comorbid disease in patients with psoriasis: a review of potential risks and benefits","volume":"12","author":"Mikhaylov D","year":"2019","journal-title":"J Clin Aesthet Dermatol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.16231","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16231","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.16231","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:40:25Z","timestamp":1791294025000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.16231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,28]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1111\/jdv.16231"],"URL":"https:\/\/doi.org\/10.1111\/jdv.16231","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,28]]},"assertion":[{"value":"2019-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}